The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema

Trial Profile

The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 300 to 309.
    • 15 Dec 2009 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top